(CNN) – The Russian Sputnik V of Russia has experienced a growing popularity in Latin America, with more countries announcing envoys and agreements to buy the vaccine against covid-19.
New countries of Latin America have now approved the use of the Sputnik V vaccine: Argentina, Bolivia, Guatemala, Guyana, Honduras, Mexico, Nicaragua, Paraguay and Venezuela. It also initiated the distribution of the vaccine in Argentina, Bolivia, Mexico, Nicaragua, Paraguay and Venezuela.
The vaccine has been approved in 39 countries all over the world, according to the Russia Direct Inversion Fund (RDIF), which seeks to commercialize the vaccine.
The Sputnik V vacuum has a price list that is economical and can maintain temperatures higher than the Pfizer vacuum, which is very attractive for Latin American countries with less developed economies and infrastructures. Require dosage of tomatoes with 21 different days for it to be effective.
Argentina was converted into the first Latin American country to distribute the Sputnik V vaccine at the end of December, with a purchase of up to 25 million doses. The country has distributed more than 600,000 doses.
Since then, Venezuela and Mexico have received 100,000 and 200,000 shares, respectively, in February. Nicaragua has begun distributing the vaccine on March 2 after receiving a donation of no dose.
Russia’s difficulty in supplementing the production of the Sputnik V vaccine
Mientras Rusia lucha por mantenerse al día con la demand, algunos paisos solo han recibido envyos myy pequeños. Bolivia receives 20,000 doses of the Sputnik V enero, although it hopes to be able to evacuate eventually to 2.6 million people. Paraguay announced the purchase of one million doses, but by now only 4,000 had been received.
Russia has reconstructed the contraction of production and has considered launching regional production centers in various countries, including Brazil, according to Kremlin spokesman Dmitry Peskov.
Expressed interest in producing the Sputnik V vaccine at the local level in Latin America. The RDIF recently announced an agreement with the Richmond Laboratories of Argentina to start producing the vacancy in the country, although it has not allocated a space for entry.
The experts repeatedly expressed their concern about the transparency of the Sputnik trial and its accelerated authorization in Russia. On the other hand, the vacancy rate was 91.6% effective against the covid-19 synthetic and 100% effective against severe and moderate illnesses, in an intermediate analysis of the results of the phase 3 interview published in The Lancet.
– Reported by Mitchell McCluskey in Atlanta, Stefano Pozzebon in Bogotá, Tatiana Arias in Atlanta and Tim Lister in Spain.